Literature DB >> 1456403

Multiple relapses of Clostridium difficile-associated diarrhea in a cancer patient. Successful control with long-term cholestyramine therapy.

M D Moncino1, J M Falletta.   

Abstract

Clostridium difficile-associated diarrhea (CDAD) is caused by a toxin elaborated by the anaerobic organism Clostridium difficile. Although the vast majority of CDAD cases are now associated with antibiotic use, the administration of antineoplastic agents alone can result in clinical manifestations. While therapy with oral vancomycin is usually successful, one quarter of patients will relapse. We describe a 16-year-old girl with osteogenic sarcoma whose therapy was significantly complicated by multiple relapses of CDAD. All resulted in hospital admission. She failed several standard therapies for relapsed CDAD and was cured only after prolonged cholestyramine therapy. A subset of multiply relapsed CDAD patients may require prolonged therapy with cholestyramine to control the disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1456403

Source DB:  PubMed          Journal:  Am J Pediatr Hematol Oncol        ISSN: 0192-8562


  12 in total

Review 1.  Gastrointestinal dysbiosis and the use of fecal microbial transplantation in Clostridium difficile infection.

Authors:  L Patrick Schenck; Paul L Beck; Justin A MacDonald
Journal:  World J Gastrointest Pathophysiol       Date:  2015-11-15

2.  Clarification of article on Clostridium difficile--associated colitis.

Authors:  Kenneth Brown
Journal:  Can Fam Physician       Date:  2005-02       Impact factor: 3.275

3.  Management of Clostridium difficile Infection.

Authors:  Layth S Al-Jashaami; Herbert L DuPont
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-10

Review 4.  From stool transplants to next-generation microbiota therapeutics.

Authors:  Elaine O Petrof; Alexander Khoruts
Journal:  Gastroenterology       Date:  2014-01-08       Impact factor: 22.682

Review 5.  Clostridium difficile infection: a common clinical problem for the general internist.

Authors:  G M Caputo; M R Weitekamp; A E Bacon; C Whitener
Journal:  J Gen Intern Med       Date:  1994-09       Impact factor: 5.128

Review 6.  Toxin-specific antibodies for the treatment of Clostridium difficile: current status and future perspectives.

Authors:  Greg Hussack; Jamshid Tanha
Journal:  Toxins (Basel)       Date:  2010-05-07       Impact factor: 4.546

7.  Residential and recreational acquisition of possible estuary-associated syndrome: a new approach to successful diagnosis and treatment.

Authors:  R C Shoemaker
Journal:  Environ Health Perspect       Date:  2001-10       Impact factor: 9.031

8.  Possible estuary-associated syndrome: symptoms, vision, and treatment.

Authors:  R C Shoemaker; H K Hudnell
Journal:  Environ Health Perspect       Date:  2001-05       Impact factor: 9.031

9.  New advances in the treatment of Clostridium difficile infection (CDI).

Authors:  Dennis D Hedge; Joe D Strain; Jodi R Heins; Debra K Farver
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

Review 10.  A review of the mechanism of injury and treatment approaches for illness resulting from exposure to water-damaged buildings, mold, and mycotoxins.

Authors:  Janette Hope
Journal:  ScientificWorldJournal       Date:  2013-04-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.